Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.

Yong-Xian ShaoCui-Li LiangYa-Ying SuYun-Ting LinZhi-Kun LuRui-Zhu LinZhi-Zi ZhouChun-Hua ZengChun-Yan TaoZong-Cai LiuWen ZhangLi Liu

Published in: Orphanet journal of rare diseases (2024)

Empagliflozin treatment for pediatric GSD Ib patients is efficient and safe. Increase of urine glucose is a signal for pharmaceutical effect, however attention to urinary infection and hypoglycemia is suggested.

Keyphrases

end stage renal disease
type diabetes
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
combination therapy
adipose tissue
replacement therapy